Xvivo Perfusion Ab · OMXSTO:XVIVO
Xvivo Perfusion Ab — Q3 2024 Earnings Presentation
26 slides from Xvivo Perfusion Ab's earnings presentation, Oct 24, 2024
Slide 1: Quarterly Report Q3 2024
Quarterly Report Q3 2024 Earnings call, October 24, 2024 Alex Moroianu Heart transplant recipient, AU
Slide 2: Today's presenters
Today’s presenters Christoffer Kristoffer Rosenblad Nordström CEO CFO 1 DOC ID: Quarterly report Jul-Sep 2024
Slide 3: Q3 Financials – at a glance
Q3 Financials – at a glance Organic growth Net Sales Thoracic Disposable sales SEK 198 Million Net Sales SEK 141 million +54% Gross margin Disposables 85% Sales growth Organic Abdominal Disposable sales growth 41% Net Sales SEK 39 million Gross margin Disposables 62% +13% - Currency effect -6% - Tot
Slide 4: YTD Financials – at a glance
YTD Financials – at a glance Organic growth Net Sales Thoracic Disposable sales SEK 595 Million Net Sales SEK 403 million +43% Gross margin Disposables 84% Sales growth Organic Abdominal Disposable sales growth 36% Net Sales SEK 130 million Gross margin Disposables 64% +31% - Currency effect -1% - T
Slide 5: Business overview Q3
Business overview Q3 4 DOC ID: Quarterly report Jul-Sep 2024
Slide 6: Results from European RCT using XVIVO heart technology published in The Lancet
Results from European RCT using XVIVO heart technology published in The Lancet Randomized control trial (RCT) with superiority design run in 15 European centres comparing static cold storage (SCS) with hypothermic oxygenated perfusion (HOPE) of the donor heart “This trial represents a significant ev
Slide 7: Results from European RCT using XVIVO heart technology published in The Lancet (key take-aways)
Results from European RCT using XVIVO heart technology published in The Lancet Additional key take-aways • After adjustment for minor differences between trial sites, the risk reduction for the primary endpoint was even more pronounced at 49% after HOPE (p 0.02) • Severe PGD, that is the leading cau
Slide 8: Expanding capabilities with HOPE
Expanding capabilities with HOPE Successful clinical transplantation of hearts donated after circulatory death using direct procurement followed by HOPE An investigator-initiated study, led by Prof. Filip Rega, with direct procurement and HOPE has been started in Europe. • 4 sites (Belgium & Netherl
Slide 9: EVLP evidence in summary
EVLP evidence in summary Increasing lung Implementation of an EVLP Outcomes with marginal acceptance rate with 10% program led to lungs transplanted after EVLP decreases waitlist 30 % increase in transplant are comparable with those of mortality by ~35% activity. standard donor lungs. Supporting evi
Slide 10: Strong momentum for EVLP
Strong momentum for EVLP EVLP growth driven by high market growth and increased customer base in the US • Record quarter for thoracic sales • 110% growth in US sales year-on-year 9 DOC ID: Quarterly report Jul-Sep 2024
Slide 11: Increasing pool of clinical evidence supports machine perfusion for Liver
Increasing pool of clinical evidence supports the use of machine perfusion for Liver • Long term outcomes from over 1200 livers using HOPE in a real- world setting display excellent long-term performance of HOPE- treatment of DCD and DBD liver grafts irrespective of their individual risk profile – s
Slide 12: XVIVO acquires communication platform FlowHawk
XVIVO acquires unique communication platform for the transplant process - FlowHawk • Complex and rapidly changing transplant system in the US requires new tools and support systems to better enable transplant teams to manage critical activities throughout the transplant process • Acquisition strengt
Slide 13: Clinical pipeline
Clinical pipeline 12 DOC ID: Quarterly report Jul-Sep 2024
Slide 14: Clinical Trial Status & Tentative Timeline
Clinical Trial Status & Tentative Timeline REVIEW & PRECLINICAL CLINICAL MARKET APPROVAL FOLLOW-UP • Trial to include 141 patients across 26 high impact centres 18 month patient 12 month patient Submission and PMA • 1st patient included in October enrollment follow-up approval process HEART 2023 • P
Slide 15: Financial Performance Q3
Financial Performance Q3 14 DOC ID: Quarterly report Jul-Sep 2024
Slide 16: Net sales and results in Q3
Net sales and results in Q3 Organic sales growth Q3 41% Jul-Sep Jul-Sep YTD YTD SEK Million 2024 2023 2024 2023 Net sales 198 147 595 442 Sales growth, % 35 % 51 % 35 % 56 % Whereof organic growth, % 41 % 37 % 36 % 39 % Gross profit 148 108 441 328 Gross margin, % 75 % 73 % 74 % 74 % EBIT (adj) 25 1
Slide 17: Thoracic – Q3 Highlights
Thoracic – Q3 Highlights Net sales by Net sales by Net sales by organ Net Sales region product category SEK 141 million (91) 2% 13% Organic growth disposables 19% 54 % (30) 5% 35% Gross margin disposables 63% 85 % (86) 87% 76% Heart Sales (SEK) Lung Heart Americas Machine perfusion 19million (4) APA
Slide 18: Abdominal – Q3 Highlights
Abdominal – Q3 Highlights Net sales by Net sales by Net Sales Net sales by organ region product category SEK 39 million (35) 13% Organic growth disposables 2% 28% 13 % (100) Gross margin disposables 62 % (61) 72% 85% 100% Liver Kidney Americas APAC Machine perfusion EMEA 17 DOC ID: Quarterly report
Slide 19: Services – Q3 Highlights
Services –Q3 Highlights Net Sales Recovery cases Q3 Case trend Net Sales Cases R12 Growth R12 SEK 18 million (21) 1 459 -21% Organic growth -7 % (68) 40 96 55 Gross margin recoveries 38 % (40) Hearts Lungs Heart-Lung block 18 DOC ID: Quarterly report Jul-Sep 2024
Slide 20: EBITDA
EBITDA July – September 2024 EBITDA (adj), R12 months EBITDA (adj), by quarter Comments SEKm SEKm 200 30% • R12 Trend continues to improve 30% 70 from continued profitability 180 improvements 25% 25% 160 151 60 137 51 • Sales growth at solid gross 140 20% 50 20% margin levels as key drivers 120 115
Slide 21: Cashflow and financial position (Sep 30, 2024)
Cashflow and financial position (Sep 30, 2024) Cash flow from Cashflow from Q3 Cashflow operating activities (R12) investing activities • Cash flow from operating SEKm activities SEK +23 million (25) 100 Q3 Q3 YTD YTD • Investments SEK -41 million (-28) 90 R12 SEKm 2024 2023 2024 2023 • Financing ac
Slide 22: Outlook
Outlook Alex Moroianu Heart transplant recipient, AU 21
Slide 23: Long term outlook
Long term outlook • The demand for transplants are x 10 of today’s supply HAT bild • Sales value of machine perfusion vs cold static storage is ~x 10 • Machine perfusion and service models have proven to increase the number of organs used for transplantation • XVIVO has unique, innovative and world
Slide 24: Outlook 2024 & 2025
Outlook 2024 & 2025 • Investing in commercial capabilities • Building strong front- and back-end organization to support growth • Expand global market leadership in lung by driving EVLP utilization • Launch heart in Europe & ANZ and continue to build US clinical and regulatory file • Expand European
Slide 25: Nobody should die waiting for a new organ
Nobody should die waiting for a new organ 24DOC ID: Quarterly report Apr-Jun 2024
Slide 26: Financial calendar & contacts
Financial calendar & contacts Financial reports 2024 & 2025 Investor Relations Kristoffer Nordström, CFO Report on Operations 2024: January 28, 2025 Telephone: +1 484 437 1277 E-mail: kristoffer.nordstrom@xvivogroup.com Interim report January – March 2025: April 24, 2025 Christoffer Rosenblad, CEO T